NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

In GBM, the standard of cares (SOC) have yielded dismal prospects/results for patients with OS around 15-18 months;

Nothing significant has been achieved over the past decades.

miraculously and mysteriously, the electric hat Optune (nvcr) had seen its controlled short live SOC, and succeeded with FDA approval for unexplained MOC and OS advantage;

All the failed pivotal P3 trials, including imuc, cldx, etc, haven't seen their control patients outlive SOC anymore significantly.

And most importantly, all P3 trials conducted so far for GMB failed, and have failed to yield any long term survival data. They usually stopped follow patients either prematurely or intentionally at convenient time. Never ever give actual long-term survival data.

On contrary, DVCax-L has promising survival data published in blended manner, and based on the above, it is already a success. On top of that, the suggested long-term survivals if confirmed will be unprecedentedly and unbelievable good.

Nobody will deny that a patient having about 35% and 20% chances of living over 3 and 5 years is not a wonderful thing in the dreaded treatment landscape of GMB.

In term of stock, $250 million market cap, and $0.34 per share is the current situation.

Buy or not, you are smart guys. Make your own decision!

[sorry sukus this post was not intended to reply to yours. instead it was intended for a stand alone one]